Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

Inclusion Criteria: * Healthy subjects, male and female * Age: 18 - 70 years (inclusive) at the time of screening. * Females of non-child bearing potential (surgically sterile \[hysterectomy or bilateral tubal ligation\] or post-menopausal \>= 1 year with follicle stimulating hormone \[FSH\] \> 40 U/L). * Healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, electrocardiogram, and clinical laboratory evaluations). * Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent and the Health Insurance Portability and Accountability Act (HIPAA) Authorization prior to performing any of the screening procedures. Exclusion Criteria: * Known allergy or hypersensitivity to beta-lactam/cephalosporin antibiotics, corn products or any of the other ingredients of the Investigational Products * Subjects with impaired renal function based on the Cockcroft-Gault formula using actual body weight, i.e. estimated creatinine clearance \<= 80 mL/min (performed at Screening only) * Body Mass Index (BMI) \< 20.0 or \> 30.0 kg/m\^2 * Body Weight \< 50.0 kg * White Blood Count (WBC) \< 3.5 x10\^3/uL or \> ULN * absolute neutrophil count (ANC) \< 1.5 x10\^3/uL or \> ULN * Alarine aminotransferase and aspartate aminotransferase \> upper limit of normal * Other laboratory tests that are outside the normal limits, considered by the investigator, to be clinically significant. * Use of any medication on a chronic basis. * Takes any medication which interferes with the study drug or study procedures including aminoglycosides, anticoagulants, and probenecids. * Use of over the counter (OTC) medications (including vitamins), prescription medications, or herbal remedies from 14 days prior to Day -1 until end of study. By exception, acetaminophen \<= 1 gram per day is permitted. * Tobacco use during the last 2 months prior to enrollment. * Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody. * Positive urine drug test (cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids, etc.) at Screening or Day -1 * Positive blood test for ethanol at screening or Day -1. * At screening, the subject has a clinically relevant ECG change, as assessed by the PI or designee. * Concurrent acute or chronic infections (e.g. viral infections, except chronic recurrent herpes infections) * History of or ongoing alcohol abuse or drug abuse (within last 2 years). * Received an Investigational drug or device within 30 days of first dose of study drug * Clinically relevant medical conditions which are likely to interfere with the evaluation of the trial drug, e.g. COPD, metabolic disorders (such as clinical and sub-clinical diabetes mellitus), history of malignant diseases (within last 5 years), autoimmune diseases, and cardiovascular disease * Any planned medical intervention or personal event that might interfere with the ability to comply with the study requirements * Any condition that, in the opinion of the principal investigator, would compromise the safety of the patient or the quality of the data * Unable or unwilling to adhere to the study-specified procedures and restrictions